	US 11,944,684 B2
	Composition for treating and/or preventing fungal infections
Anders Carlsson, Stockholm (SE); and Dan Markusson, Växjö (SE)
Assigned to PEPTONIC MEDICAL AB, Bromma (SE)
Appl. No. 18/251,929
Filed by PEPTONIC MEDICAL AB, Bromma (SE)
PCT Filed Nov. 5, 2021, PCT No. PCT/EP2021/080740 § 371(c)(1), (2) Date May 5, 2023, PCT Pub. No. WO2022/096632, PCT Pub. Date May 12, 2022.
Claims priority of application No. 2051299-2 (SE), filed on Nov. 9, 2020.
Prior Publication US 2023/0321247 A1, Oct. 12, 2023
Int. Cl. A61K 47/38 (2006.01); A61K 31/192 (2006.01); A61P 31/04 (2006.01); A61P 31/10 (2006.01); A61K 9/08 (2006.01)

CPC A61K 47/38 (2013.01) [A61K 31/192 (2013.01); A61P 31/04 (2018.01); A61P 31/10 (2018.01); A61K 9/08 (2013.01)]

15 Claims

1. A method for the treatment and/or prevention of a human fungal infection, said method comprising administering to a patient in need thereof an effective amount of an aqueous composition comprising:

(a) at least one non-ionic cellulose ether, said at least one non-ionic cellulose ether being hydroxypropylmethylcellulose (HPMC), and

(b) an active pharmaceutical agent being benzoic acid within the range of from 0.2 wt % to 0.3 wt % based on the total weight of the composition,

wherein said composition has a viscosity equal to or above 24 000 cP, an osmolality of from 100 to 400 mOsmol/kg, and a pH of from 3 to 5,

wherein the aqueous composition does not comprise an additional active pharmaceutical agent other than benzoic acid.